FINWIRES · TerminalLIVE
FINWIRES

Lululemon's Soft Fiscal Q2, Lowered 2026 Outlook Prompt Caution, Oppenheimer Says

By

Lululemon Athletica (LULU) reported softer-than-planned fiscal Q2 results and lowered its fiscal 2026 guidance again, prompting a cautious stance on the stock, as the delayed start of incoming CEO Heidi O'Neill leaves the company a "rudderless ship" and risks further competitive disintermediation amid deteriorating macro conditions, Oppenheimer said Friday.

Underlying fiscal Q2 results and management's more downbeat tone toward the rest of the fiscal year proved weaker than Oppenheimer's already dampened expectations, according to the note.

While recent data points to a more challenging macro backdrop impacting sales growth across the athleisure industry, the brokerage believes the incremental top- and bottom-line weakness at Lululemon is primarily due to internal missteps in merchandising and marketing, the note added.

Management noted that demand in North America was even softer in August and expects fiscal Q3 comparable sales in the region to decline at a mid-teens rate, versus a 12% decline in fiscal Q2, the brokerage said.

Revised fiscal 2026 guidance for adjusted EPS of $8.62 to $8.87 compares with expectations at the beginning of the year for earnings of $12.10 to $12.30, a decline of nearly 30%, the brokerage added.

Oppenheimer kept a perform rating on Lululemon Athletica.

Shares of Lululemon Athletica were down approximately 18% in Friday trading.

Price: $99.61, Change: $-22.17, Percent Change: -18.20%

Related Articles

Wire

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

Vaxcyte (PCVX) appointed Luis Jodar as chief medical officer and David McAvoy as chief legal officer, the company said on Thursday.Jodar spent 17 years at Pfizer (PFE), most recently as senior vice president and chief medical officer for Vaccines and Infectious Diseases, the company said.McAvoy joins the company from Teva Pharmaceutical (TEVA), according to a statement.The vaccine developer also said it now expects to report topline data from its phase 3 OPUS-1 trial of VAX-31 in adults by the end of October, narrowing its previous guidance of a Q4 data release.

$PCVX
Wire

eGain Fiscal Q4 Adjusted Earnings, Revenue Fall; Shares Slump After Hours

EGain (EGAN) reported fiscal Q4 adjusted earnings late Thursday of $0.08 per diluted share, down from $0.09 a year earlier.Three analysts polled by FactSet projected $0.03.Revenue in the three months ended June 30 fell to $22.2 million from $23.2 million a year earlier.Three analysts projected $21.7 million.The company expects fiscal Q1 adjusted EPS of $0.05 to $0.08 on revenue of $20.9 million to $21.4 million. Three analysts project EPS of $0.08 on revenue of $22.3 million.For fiscal 2027, eGain expects adjusted EPS of $0.04 to $0.07 on revenue of $84.5 million to $86 million. Three analysts project EPS of $0.43 on revenue of $94.1 million.EGain shares slumped 29% in after-hours trading.

$EGAN
Wire

American Outdoor Brands Fiscal Q1 Swings to Adjusted Earnings, Revenue Rises

American Outdoor Brands (AOUT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.03 per diluted share, swinging from a loss $0.26 year earlier.Two analysts polled by FactSet expected a loss of $0.24.Net sales for the quarter ended July 31 were $37.3 million, up from $29.7 million a year earlier.Two analysts expected $35.6 million.For fiscal 2027, the company maintained its net sales forecast of $200 million to $210 million. Two analysts expect $205.1 million.Shares of the company rose over 16% in after-hours trading.

$AOUT